Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib.
Biomolecular NMR assignments (2008)
- PubMed: 19636920
Available from www.ncbi.nlm.nih.gov
or
Abstract
Imatinib (Glivec or Gleevec) potently inhibits the tyrosine kinase activity of BCR-ABL, a constitutively activated kinase, which causes chronic myelogenous leukemia (CML). Here we report the first almost complete backbone assignment of c-ABL kinase domain in complex with imatinib.
Sign up today - FREE
Mendeley saves you time finding and organizing research. Learn more
- All your research in one place
- Add and import papers easily
- Access it anywhere, anytime
Start using Mendeley in seconds!
Readership Statistics
3 Readers on Mendeley
by Discipline
33% Chemistry
by Academic Status
67% Post Doc
33% Researcher (at a non-Academic Institution)
by Country
67% United States
33% Germany